-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Hold on Immunovant, Raises Price Target to $30

Benzinga·05/22/2026 15:41:00
Listen to the news
Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $23 to $30.